Arena Pharmaceuticals Inc. (ARNA): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Arena Pharmaceuticals ( ARNA) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.3%. By the end of trading, Arena Pharmaceuticals fell 23 cents (-2.5%) to $8.96 on light volume. Throughout the day, eight million shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 10.8 million shares. The stock ranged in price between $8.93-$9.33 after having opened the day at $9.23 as compared to the previous trading day's close of $9.19. Other companies within the Health Care sector that declined today were: Dehaier Medical Systems ( DHRM), down 20.4%, Amyris ( AMRS), down 9.7%, Arrhythmia Research Technology ( HRT), down 9.1%, and BioDelivery Sciences International ( BDSI), down 8.9%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $2.07 billion and is part of the drugs industry. Shares are up 391.4% year to date as of the close of trading on Friday. Currently there are two analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and six rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been poor profit margins.

On the positive front, Stereotaxis ( STXS), up 54.5%, Thermogenesis Corporation ( KOOL), up 17.6%, ZIOPHARM Oncology ( ZIOP), up 15.4%, and Lpath ( LPTN), up 15.4%, were all gainers within the health care sector with Aetna ( AET) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

These Stocks Have Changed Direction

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says